Evaluation of lipids, drug concentration, and safety parameters following cessation of treatment with the cholesteryl ester transfer protein inhibitor anacetrapib in patients with or at high risk for coronary heart disease

Evaluation of lipids, drug concentration, and safety parameters following cessation of treatment with the cholesteryl ester transfer protein inhibitor anacetrapib in patients with or at high risk for coronary heart disease

Item

http://www.wikidata.org/entity/Q28301320

Q28301320

about

Randomized Evaluation of the Effects of Anacetrapib through Lipid-modification (REVEAL)-A large-scale, randomized, placebo-controlled trial of the clinical effects of anacetrapib among people with established vascular disease: Trial design, recruitm HDL and cognition in neurodegenerative disorders.Effects of the cholesteryl ester transfer protein inhibitor evacetrapib on lipoproteins, apolipoproteins and 24-h ambulatory blood pressure in healthy adults Evolving targets for lipid-modifying therapy HDL surface lipids mediate CETP binding as revealed by electron microscopy and molecular dynamics simulation.The pharmacokinetics and pharmacokinetic/pharmacodynamic relationships of evacetrapib administered as monotherapy or in combination with statins.The ebbs and flows in the development of cholesterol-lowering drugs: prospects for the future.High-density lipoproteins in the prevention of cardiovascular disease: changing the paradigm.Beyond statins: new lipid lowering strategies to reduce cardiovascular risk.Looking into the crystal ball-upcoming drugs for dyslipidemia.Revising the high-density lipoprotein targeting strategies - insights from human and preclinical studies.Emerging drugs for hyperlipidaemia: an update.Lipids, safety parameters, and drug concentrations after an additional 2 years of treatment with anacetrapib in the DEFINE study.High Density Lipoprotein Cholesterol Increasing Therapy: The Unmet Cardiovascular Need.Promising new therapies for the treatment of hypercholesterolemia.CETP Inhibition in CVD Prevention: an Actual Appraisal.Mendelian Randomization Implicates High-Density Lipoprotein Cholesterol-Associated Mechanisms in Etiology of Age-Related Macular Degeneration.New directions for pharmacotherapy in the treatment of acute coronary syndrome.Cholesteryl Ester Transfer Protein Inhibitors: Trials and Tribulations.Cholesteryl ester transfer protein inhibitors: challenges and perspectives.Pharmacokinetic drug evaluation of anacetrapib for the treatment of dyslipidemia.Dietary Strategies and Novel Pharmaceutical Approaches Targeting Serum ApoA-I Metabolism: A Systematic Overview Assessment of the persistence of anacetrapib and evacetrapib concentrations using two pharmacokinetic modeling approaches.HyperLp(a)lipoproteinaemia: unmet need of diagnosis and treatment?Disposition into Adipose Tissue Determines Accumulation and Elimination Kinetics of the Cholesteryl Ester Transfer Protein Inhibitor Anacetrapib in Mice.HDL-cholesterol levels and risk of age-related macular degeneration: a multiethnic genetic study using Mendelian randomization.Chronic Administration of Anacetrapib Is Associated With Accumulation in Adipose and Slow Elimination.HDL Mimetics Infusion and Regression of Atherosclerosis: Is It Still Considered a Valid Therapeutic Option?

P2860

Q33643426-36E4929E-D1DA-4DAC-B71E-D86178CE389D Q34614842-C729784E-3D88-4139-85FB-47EEA6300407 Q34823459-06A0ADB9-E5E3-463C-9BA1-1DCC3F86AC19 Q34880292-5630FE4D-5418-43C7-9CC7-0457D2BF89A7 Q35144318-78827B27-952C-45AC-B2A1-922A519253CE Q37541793-5BAEB9D3-43EF-4E59-9633-87E215E23005 Q38201960-6861AA23-AA0E-41D8-A541-8E3DDFCF95CE Q38203096-63DE8D5B-AF26-4C85-9B8A-573B14D7113A Q38207925-639AED85-7A12-46B8-B0B5-685D01B798D9 Q38235611-624B5E26-CA6C-487D-BBD0-8B93F173F803 Q38239205-2843D2E9-3FB5-468A-98F8-3333A364EC06 Q38263909-24BA3492-121E-4103-B684-330BB4FA3E55 Q38439249-FC76315A-55AF-4D6D-A18C-69D7D6D24F39 Q38624772-D06E5DF7-0520-47D0-A3C8-0B5E7F361218 Q38715252-CDB1CB15-471A-4142-82B5-BDD8248B3C21 Q38784639-97DC4379-7936-418A-8F74-53FD5E45699B Q38812921-CD69240E-4623-449F-B439-0990FFDDF6C5 Q38817144-AC2852E1-6559-430B-9D92-52566596152E Q38832478-B4B927B0-0715-4CCC-8DC8-AA8FECB50DE6 Q38832774-55F43C39-9C2B-4C80-AF1F-FC9658F02E93 Q39010254-E46100D6-7C1A-40FF-838E-4D346C926665 Q39427274-E365F446-81F5-4E01-848A-5B45B1FE593F Q41479614-61066D5C-605F-48EB-8C8A-A08865ECE9E3 Q42396853-10A79497-F6C2-4EC2-955C-97AC460E6B39 Q49087277-2001F593-2C23-4400-8167-1BC0FD69092F Q50100117-F48C5889-F873-4654-988A-177DC26B5331 Q50747614-4DC22B7B-BD86-496B-9625-E5C110CFE517 Q55257404-B6DE3014-5668-4E60-8A6E-1941254E91D6

P2860

Evaluation of lipids, drug concentration, and safety parameters following cessation of treatment with the cholesteryl ester transfer protein inhibitor anacetrapib in patients with or at high risk for coronary heart disease

Item

http://www.wikidata.org/entity/Q28301320

description

2014 nî lūn-bûn

@nan

2014 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu